

## New insights into the regulation of apoptosis, necroptosis and pyroptosis by RIPK1 and caspase-8

Robin Schwarzer<sup>1</sup>, Lucie Laurien<sup>1</sup> and Manolis Pasparakis<sup>1,2</sup>

<sup>1</sup>Institute for Genetics & Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.

<sup>2</sup>Center for Molecular Medicine (CMMC), University of Cologne, Cologne, Germany.

Correspondence: [pasparakis@uni-koeln.de](mailto:pasparakis@uni-koeln.de)

### Summary

Necroptosis and pyroptosis are inflammatory forms of regulated necrotic cell death as opposed to apoptosis that is generally considered immunologically silent. Recent studies revealed unexpected links in the pathways regulating and executing cell death in response to activation of signalling cascades inducing apoptosis, necroptosis and pyroptosis. Emerging evidence suggests that RIPK1 and caspase-8 control the cross-talk between apoptosis, necroptosis and pyroptosis and determine the type of cell death induced in response to activation of cell death signalling.

### Introduction

Cell death is an essential biological process for multicellular organisms including fungi, plants and animals [1], with important functions for development, tissue homeostasis and host defence. This article focuses on recent developments on cell death regulation and function in mice and humans with particular emphasis on the role of cell death in tissue homeostasis, inflammation and disease. Apoptosis was the first pathway of regulated cell death identified, initially described based on its distinct morphological features including cytoplasmic and nuclear condensation, membrane blebbing and the formation of apoptotic bodies. The discovery that apoptosis was induced by specific cysteinyl aspartate proteases termed caspases provided the proof that this type of cell death is controlled by distinct molecular machineries and should be considered a form of cellular suicide. Two pathways of apoptosis have been described based on the upstream initiator caspases that induce them [2]. Extrinsic apoptosis is induced by caspases 8 and 10, which are activated mostly in response to death receptor stimulation, while intrinsic apoptosis is induced by caspase-9, which is activated by cytochrome c released to the cytosol in response to mitochondrial outer membrane permeabilisation (MOMP). Initiator caspases activate the effector caspases 3, 6 and 7, which proteolytically process multiple cellular substrates to induce the controlled demise of the cell [2].

Until recently, apoptosis was considered the only molecularly controlled type of cell death, as opposed to necrosis that was classically described as non-regulated accidental cell death. However, genetic, biochemical and functional evidence as well

as the discovery of specific chemical inhibitors of necrotic cell death have redefined necrosis as a molecularly controlled form of cell death [3,4]. Several types of regulated necrotic cell death have been recently identified, which share common morphological features, including increase of the cellular volume, swelling of organelles and disruption of the plasma membrane, but are activated in response to different triggers and are executed by distinct biochemical pathways [4]. Necroptosis is a form of regulated necrotic cell death induced by receptor interacting protein kinase 3 (RIPK3) and its substrate mixed lineage kinase-like (MLKL) [3]. RIPK3 is activated by upstream pathways via RIP homotypic interaction motif (RHIM)-dependent protein-protein interactions with the three additional proteins in the mammalian genome that contain conserved RHIMs, namely RIPK1, TRIF and ZBP1/DAI [3,5]. RIPK1 links RIPK3 to death receptor (DR) signalling, TRIF mediates RIPK3 activation downstream of TLR3 and TLR4, whilst ZBP1/DAI mediates RIPK3 activation primarily in response to certain viruses [3,5]. Necroptosis execution requires the RIPK3-dependent phosphorylation of MLKL, which subsequently damages the plasma membrane via poorly understood mechanisms inducing the death of the cell [3,5].

Pyroptosis is a type of regulated necrotic cell death induced by inflammatory caspases, namely caspase-1 as well as caspase-11 (in mouse cells) or caspase-4 and caspase-5 (in human cells) [2]. Both caspase-1 and caspase-11 (or caspases-4, -5) induce pyroptosis by proteolytically processing Gasdermin D (GSDMD) yielding an N-terminal fragment that opens pores on the plasma membrane leading to cell death [6,7]. In addition to cleaving GSDMD, caspase-1 processes the precursor cytokines pro-IL-1 $\beta$  and pro-IL-18 to produce the mature bioactive forms that are released through the GSDMD pores and the lysed cells triggering inflammation [2]. Pyroptotic cell death is triggered by the assembly and activation of inflammasomes, macromolecular protein complexes that serve as platforms for the activation of caspase-1. The NOD-like receptors (NLRs) Nlrp3, Nlrp1b and Nlrc4, the cytosolic DNA sensor AIM2 (absent in melanoma 2) as well as Pypin, engage the so-called canonical inflammasomes by recruiting and activating caspase-1 either directly or through the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD) [2]. The non-canonical inflammasome is triggered by intracellular lipopolysaccharide (LPS), which activates caspase-11 (caspase-4, -5 in human cells) [2].

These developments have sparked a large number of studies addressing the mechanisms regulating the different types of regulated cell death and their role in physiology and disease, which have been covered in a number of comprehensive reviews during the last years [3,5,8-10]. The aim of the present short article is not to comprehensively cover the large literature on cell death, but rather to discuss most recent studies that shed light on new mechanisms regulating and connecting necroptosis and pyroptosis, focusing particularly on the role of caspase-8 and RIPK1 as essential players in a complex network of cell death signalling.

### **RIPK1 regulation by ubiquitination and phosphorylation**

RIPK1 functions as a signalling hub within apoptotic and necroptotic cell death pathways and exhibits kinase-dependent and -independent functions that are important for the regulation of cell survival, cell death and inflammation. Studies in

genetic mouse models showed that RIPK1 acts as a scaffold independently of its kinase activity to prevent apoptosis and necroptosis in different tissues and that this function is important for preventing inflammation and maintaining tissue homeostasis [11-19]. Children with RIPK1 deficiency were found to suffer from severe immunodeficiency and autoinflammatory pathologies [20-22], suggesting that RIPK1 scaffold functions are essential for tissue homeostasis also in humans. On the other hand, genetic and pharmacological inhibition of RIPK1 kinase activity revealed an important role of RIPK1 kinase-dependent apoptosis and necroptosis in driving inflammatory and degenerative pathologies in multiple tissues [23-30]. These studies highlighted the important but opposing roles of RIPK1 in preventing or promoting cell death and suggested that the balance between its kinase-independent and -dependent functions must be tightly regulated to ensure tissue homeostasis and prevent cell death and disease.

Several studies revealed that ubiquitination of RIPK1 with lysine 63 (K63), K11, K48 as well as M1 (linear) ubiquitin chains regulates its function by promoting its pro-survival role within the TNFR1 signalling complex and preventing the formation of death-inducing protein complexes. In particular, the role of K63 and linear ubiquitin chains has been thoroughly investigated biochemically and genetically in numerous studies that could not be covered in this short article but have been discussed extensively in recent reviews [31-35]. Two recent studies revealed that mutation of lysine 376 of RIPK1, which was shown to be ubiquitinated by K63-linked chains [36], in murine RIPK1 caused embryonic lethality that was fully prevented by combined inhibition of caspase-8-mediated apoptosis and RIPK3-MLKL-dependent necroptosis [37,38], providing functional evidence that K376 (K377 in humans) is a critical residue for ubiquitin-dependent regulation of RIPK1.

In addition to ubiquitination, multiple phosphorylation events are implicated in regulating RIPK1 function. Three independent studies reported that phosphorylation of RIPK1 by MK2 on multiple serine residues in the intermediate domain including serine 321 in mouse (320 in human) restrains its kinase activity and cell death-inducing potential [39-41]. TAK1 was also suggested to mediate RIPK1 phosphorylation [42], but it remains unclear if this function of TAK1 is indirect by inducing MK2-dependent RIPK1 phosphorylation. Furthermore, RIPK1 phosphorylation by I $\kappa$ B kinases (IKKs) on multiple residues including serine 25 was reported to prevent RIPK1-mediated cell death [43]. Mutation of serine 25 of RIPK1 to glutamic acid to mimic phosphorylation indeed protected cells and mice from TNFR1-mediated cell death and inflammation by inhibiting RIPK1 kinase activity [44]. These reports revealed the important role of IKK-mediated phosphorylation in preventing RIPK1-mediated cell death and inflammation, consistent with studies showing that mice with tissue specific knockout of IKK subunits developed inflammatory pathologies due to RIPK1-mediated cell death [26,29]. Two independent recent studies showed that TBK1 and IKK $\epsilon$  also phosphorylate RIPK1 to suppress its cytotoxic potential [45,46], a function important during embryonic development as TBK1-deficient mice die between embryonic days 13.5 and 14.5 due to RIPK1 kinase dependent cell death [45]. Together, these studies revealed that RIPK1 ubiquitination and phosphorylation prevent the activation of RIPK1 kinase activity, which induces cell death by both apoptosis and necroptosis. Autophosphorylation is considered to be the critical function of RIPK1 kinase activity, with multiple residues identified as autophosphorylation sites in human (serines 14/15,

20, 161 and 166) and mouse (serines 14/15, 161 and 166 as well as threonine 169) RIPK1 [30,44,47,48]. Mechanistically, autophosphorylation is currently thought to impose a conformational change in RIPK1 facilitating the formation of the signalling complexes inducing apoptosis and necroptosis, however the specific function of individual autophosphorylation events remains to be experimentally validated in relevant *in vivo* models.

### **Caspase-8 cleaves RIPK1 to prevent cell death and inflammation**

Caspase-8 inhibits necroptosis but the underlying mechanisms remain poorly understood. Caspase-8 was shown to cleave several proteins involved in the regulation of necroptosis, including RIPK1 [49], RIPK3 [50], CYLD [51] and cFLIP [52], however, the role of these cleavage events in the regulation of cell death and inflammation have remained unknown until recently. Four independent studies have now identified RIPK1 as a critical substrate that is cleaved by caspase-8 to prevent excessive cell death and inflammation [53-56] (**Figure 1**). In three of these studies, the authors generated knock-in mice expressing RIPK1 with mutation of aspartic acid at position 325 to alanine (D325A), which prevents its cleavage by caspase-8, and found that these mice died between embryonic days E10.5-E12.5 [53,55,56]. The embryonic lethality of *Ripk1*<sup>D325A/D325A</sup> mice could not be rescued by RIPK3 or MLKL deficiency but could be fully prevented by combined inhibition of FADD-caspase-8-mediated apoptosis and RIPK3-MLKL-mediated necroptosis [53,55,56], showing that caspase-8-dependent cleavage of RIPK1 prevents both apoptosis and necroptosis. Interestingly, mice expressing RIPK1 with combined mutations inhibiting both its kinase activity (D138N) and caspase-8-mediated cleavage (D325A) developed to term but exhibited severe systemic inflammatory pathology resulting in early postnatal death [55,56], suggesting that inhibition of RIPK1 cleavage triggers cell death and inflammation by both kinase-dependent and -independent functions. Consistent with the genetic studies, mouse embryonic fibroblasts expressing RIPK1 with mutation of D325 underwent both apoptosis and necroptosis in response to TNF stimulation [54-56]. Notably, patients with heterozygous missense mutations of the caspase-8 cleavage site of human RIPK1 (D324) were reported to suffer from a syndrome characterised by periodic fever and lymphadenopathy [54,56], revealing that RIPK1 cleavage by caspase-8 has a critical physiological role in preventing inflammation also in humans. Together, these studies identified RIPK1 cleavage by caspase-8 as a critical event that limits RIPK1-dependent cell death and inflammation in both mice and humans. Mechanistically, RIPK1 cleavage seems to limit apoptosis and necroptosis by dismantling the respective cell death inducing signalling complexes (**Figure 1**).

### **Caspase-8 inhibits inflammasome activation**

In addition to its functions in inducing apoptosis and inhibiting necroptosis, recent studies revealed a novel role of caspase-8 in inhibiting inflammasome activation [57,58] (**Figure 1**). Knock-in mice expressing caspase-8 with mutation of its catalytic cysteine (C362) died at around embryonic day 10.5 similarly to mice lacking caspase-8 or FADD [55,57,58]. However, while MLKL deficiency could rescue embryonic lethality and support survival of caspase-8 or FADD knockout mice to adulthood[59],

MLKL knockout could only prolong the survival of mice expressing catalytically inactive caspase-8 until birth [55,57,58]. This finding suggested that necroptosis-independent mechanisms caused perinatal death of mice expressing catalytically deficient caspase-8. Formation of ASC specks was detected in tissues from these animals [57,58], suggesting that inflammasome activation could contribute to the pathology. Indeed, mice expressing catalytically inactive caspase-8 could survive to adulthood when crossed into combined *Mik1<sup>-/-</sup> Asc<sup>-/-</sup>* or *Mik1<sup>-/-</sup> Caspase-1<sup>-/-</sup>* genetic backgrounds [57,58], showing that ASC-Caspase-1-dependent mechanisms cause perinatal lethality in these mice. Furthermore, mice expressing catalytically inactive caspase-8 specifically in intestinal epithelial cells (IECs) were viable and showed mild intestinal inflammation, however when these mice were crossed into an *Mik1<sup>-/-</sup>* genetic background they died perinatally and showed formation of ASC specks and expression of IL-1 $\beta$  in their intestines [57,58], suggesting that inhibition of necroptosis was detrimental by causing increased activation of the inflammasome. A rational interpretation of these results is that IECs expressing catalytically inactive caspase-8, which would normally undergo necroptosis, persist in the absence of MLKL and by mechanisms that depend on the presence of catalytically inactive caspase-8 but remain poorly understood ASC is activated inducing caspase-1-dependent inflammatory pathology. Interestingly, gasdermin D (GSDMD) deficiency could not rescue the *Casp8<sup>C362A/C362A</sup> Mik1<sup>-/-</sup>* mice [57], suggesting that ASC and caspase-1 mediate the pathology by pyroptosis-independent mechanisms. Moreover, RIPK3 deficiency could rescue mice expressing catalytically inactive caspase-8 to adulthood [57,58], suggesting that necroptosis-independent functions of RIPK3 contribute to the activation of the ASC-caspase-1 inflammasome. Taken together, these studies revealed another layer of cell death regulation controlled by caspase-8, which acts in a catalytic activity-dependent manner to restrain the activation of the ASC-caspase-1 inflammasome. Catalytically inactive caspase-8 acts as a scaffold to induce ASC-caspase-1 activation, though the underlying molecular mechanisms remain elusive. Interestingly, necroptosis seems to act as a mechanism inhibiting inflammation in the intestinal epithelium by limiting ASC-caspase-1 activation by catalytically inactive caspase-8. Caspase-8-deficient patients were found to suffer from immune deregulation, lymphocytic infiltrations in multiple organs and very early onset inflammatory bowel disease [60-62], showing that caspase-8 has critical functions for the maintenance of immune homeostasis, in particular in the intestine, also in humans.

### **Cross-talk between apoptosis, necroptosis and pyroptosis**

Despite the progress made in delineating the molecular machineries controlling and executing apoptosis, necroptosis and pyroptosis, the cross-talk between these cell death pathways has not been appreciated until lately. Recent findings provided evidence that these cell death pathways are interconnected at multiple levels and can be activated simultaneously or consecutively within the same cell (**Figure 1**). Caspase-3, the executioner caspase in apoptosis, was shown to cleave and activate GSDME resulting in pyroptosis-like necrotic cell death in cells expressing sufficient amounts of GSDME [63,64], a phenomenon suggested to contribute to tissue damage in response to chemotherapeutic agents [63]. Caspase-8 was also recently suggested to cleave and activate GSDMD inducing pyroptosis in response to activation of the extrinsic

apoptosis signalling pathway [65-67]. An increased complexity of the regulation of GSDMD activation was revealed by experiments showing that caspase-3 cleaves GSDMD within its N-terminal domain thus limiting GSDMD-induced pyroptosis [65,68]. These studies revealed that apoptotic caspases such as caspase-8 and caspase-3 can also trigger pyroptosis-like necrotic death in cells expressing GSDME and GSDMD, suggesting that the type of cell death induced is not determined by the caspases activated but by the availability of different caspase substrates that execute apoptotic or necrotic forms of cellular demise.

A link between RIPK3-MLKL-induced necroptosis and NLRP3 inflammasome activation was suggested by studies showing that caspase-8 deficiency or treatment with caspase inhibitors caused NLRP3 activation that depended on RIPK3 and/or MLKL expression [69,70]. Although different mechanisms were proposed to explain this role of RIPK3 and MLKL, a recent study convincingly demonstrated that MLKL-mediated permeabilisation of the plasma membrane triggers NLRP3 activation by inducing potassium efflux [71]. MLKL-dependent activation of the NLRP3 inflammasome was shown to be physiologically important in mice with myeloid cell specific knockout of A20, where MLKL knockout could prevent NLRP3-Caspase-1-dependent arthritis development [72]. Moreover, a number of studies reported that exposure of myeloid cells to agents promoting extrinsic or intrinsic apoptosis caused activation of NLRP3 resulting in inflammatory cell death [73-78], suggesting that apoptosis is also linked to inflammasome activation. Activation of the extrinsic and intrinsic apoptotic pathways was suggested to induce NLRP3 activation by activating pannexin-1 channel formation on the plasma membrane resulting in potassium efflux [65].

### **Concluding remarks**

Together, the recent studies discussed here revealed new mechanisms regulating cell death, highlighting the complexity and plasticity of the pathways controlling if and how a cell dies. A key take home message is that cell death pathways do not operate in isolation as linear signalling cascades as often depicted in schematic models. On the contrary, the pathways regulating the different modalities of cell death are interconnected at multiple levels. The final outcome of a cell death inducing stimulus will depend on many parameters related to the expression and activation state of many factors that will determine if and how the cell dies. In certain cases, more than one cell death pathways may be induced in parallel influencing the immunogenic properties of the dying cells. This plasticity in simultaneously engaging diverse cell death pathways provides the cell with the capacity to fine-tune the cross-talk between dying and bystander cells in the tissue microenvironment and eliciting optimal responses ensuring effective tissue regeneration and host defence with minimal tissue damage. Elucidating the underlying mechanisms will be important in order to understand the role of cell death pathways in physiology and disease and exploit this knowledge for developing novel therapeutic approaches.

## References

1. Hofmann K: **The Evolutionary Origins of Programmed Cell Death Signaling.** *Cold Spring Harb Perspect Biol* 2019.
2. Van Opdenbosch N, Lamkanfi M: **Caspases in Cell Death, Inflammation, and Disease.** *Immunity* 2019, **50**:1352-1364.
3. Pasparakis M, Vandenabeele P: **Necroptosis and its role in inflammation.** *Nature* 2015, **517**:311-320.
4. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P: **Regulated necrosis: the expanding network of non-apoptotic cell death pathways.** *Nat Rev Mol Cell Biol* 2014, **15**:135-147.
5. Grootjans S, Vanden Berghe T, Vandenabeele P: **Initiation and execution mechanisms of necroptosis: an overview.** *Cell Death Differ* 2017, **24**:1184-1195.
6. Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, Zhuang Y, Cai T, Wang F, Shao F: **Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death.** *Nature* 2015, **526**:660-665.
7. Kayagaki N, Stowe IB, Lee BL, O'Rourke K, Anderson K, Warming S, Cuellar T, Haley B, Roose-Girma M, Phung QT, et al.: **Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling.** *Nature* 2015, **526**:666-671.
8. Green DR: **The Coming Decade of Cell Death Research: Five Riddles.** *Cell* 2019, **177**:1094-1107.
9. Newton K: **Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation.** *Cold Spring Harb Perspect Biol* 2019.
10. Peltzer N, Walczak H: **Cell Death and Inflammation - A Vital but Dangerous Liaison.** *Trends Immunol* 2019, **40**:387-402.
11. O'Donnell JA, Lehman J, Roderick JE, Martinez-Marin D, Zelic M, Doran C, Hermance N, Lyle S, Pasparakis M, Fitzgerald KA, et al.: **Dendritic Cell RIPK1 Maintains Immune Homeostasis by Preventing Inflammation and Autoimmunity.** *J Immunol* 2018, **200**:737-748.
12. Newton K, Wickliffe KE, Maltzman A, Dugger DL, Strasser A, Pham VC, Lill JR, Roose-Girma M, Warming S, Solon M, et al.: **RIPK1 inhibits ZBP1-driven necroptosis during development.** *Nature* 2016, **540**:129-133.
13. Lin J, Kumari S, Kim C, Van TM, Wachsmuth L, Polykratis A, Pasparakis M: **RIPK1 counteracts ZBP1-mediated necroptosis to inhibit inflammation.** *Nature* 2016, **540**:124-128.
14. Takahashi N, Vereecke L, Bertrand MJ, Duprez L, Berger SB, Divert T, Goncalves A, Sze M, Gilbert B, Kourula S, et al.: **RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis.** *Nature* 2014, **513**:95-99.
15. Roderick JE, Hermance N, Zelic M, Simmons MJ, Polykratis A, Pasparakis M, Kelliher MA: **Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis.** *Proc Natl Acad Sci U S A* 2014, **111**:14436-14441.
16. Rickard JA, O'Donnell JA, Evans JM, Lalaoui N, Poh AR, Rogers T, Vince JE, Lawlor KE, Ninnis RL, Anderton H, et al.: **RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis.** *Cell* 2014, **157**:1175-1188.
17. Kaiser WJ, Daley-Bauer LP, Thapa RJ, Mandal P, Berger SB, Huang C, Sundararajan A, Guo H, Roback L, Speck SH, et al.: **RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition.** *Proc Natl Acad Sci U S A* 2014, **111**:7753-7758.
18. Dillon CP, Weinlich R, Rodriguez DA, Cripps JG, Quarato G, Gurung P, Verbist KC, Brewer TL, Llambi F, Gong YN, et al.: **RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3.** *Cell* 2014, **157**:1189-1202.

19. Dannappel M, Vlantis K, Kumari S, Polykratis A, Kim C, Wachsmuth L, Eftychi C, Lin J, Corona T, Hermance N, et al.: **RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis**. *Nature* 2014, **513**:90-94.
20. Uchiyama Y, Kim CA, Pastorino AC, Ceroni J, Lima PP, de Barros Dorna M, Honjo RS, Bertola D, Hamanaka K, Fujita A, et al.: **Primary immunodeficiency with chronic enteropathy and developmental delay in a boy arising from a novel homozygous RIPK1 variant**. *J Hum Genet* 2019, **64**:955-960.
- .. This study reported that human RIPK1 deficiency caused enteropathy and primary immunodeficiency.
21. Li Y, Fuhrer M, Bahrami E, Socha P, Klaudel-Dreszler M, Bouzidi A, Liu Y, Lehle AS, Magg T, Hollizeck S, et al.: **Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases**. *Proc Natl Acad Sci U S A* 2019, **116**:970-975.
- .. This study reported that human RIPK1 deficiency caused intestinal inflammation combined with immunodeficiency
22. Cuchet-Lourenco D, Eletto D, Wu C, Plagnol V, Papapietro O, Curtis J, Ceron-Gutierrez L, Bacon CM, Hackett S, Alsaleem B, et al.: **Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation**. *Science* 2018, **361**:810-813.
- .. This study reported that human RIPK1 deficiency caused immunodeficiency combined with autoinflammatory pathologies.
23. Zhang S, Su Y, Ying Z, Guo D, Pan C, Guo J, Zou Z, Wang L, Zhang Z, Jiang Z, et al.: **RIP1 kinase inhibitor halts the progression of an immune-induced demyelination disease at the stage of monocyte elevation**. *Proc Natl Acad Sci U S A* 2019, **116**:5675-5680.
24. Taraborrelli L, Peltzer N, Montinaro A, Kupka S, Rieser E, Hartwig T, Sarr A, Darding M, Draber P, Haas TL, et al.: **LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L**. *Nat Commun* 2018, **9**:3910.
25. Li D, Meng L, Xu T, Su Y, Liu X, Zhang Z, Wang X: **RIPK1-RIPK3-MLKL-dependent necrosis promotes the aging of mouse male reproductive system**. *Elife* 2017, **6**.
26. Vlantis K, Wullaert A, Polykratis A, Kondylis V, Dannappel M, Schwarzer R, Welz P, Corona T, Walczak H, Weih F, et al.: **NEMO Prevents RIP Kinase 1-Mediated Epithelial Cell Death and Chronic Intestinal Inflammation by NF-kappaB-Dependent and -Independent Functions**. *Immunity* 2016, **44**:553-567.
27. Newton K, Dugger DL, Maltzman A, Greve JM, Hedehus M, Martin-McNulty B, Carano RA, Cao TC, van Bruggen N, Bernstein L, et al.: **RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury**. *Cell Death Differ* 2016, **23**:1565-1576.
28. Ito Y, Ofengeim D, Najafov A, Das S, Saberi S, Li Y, Hitomi J, Zhu H, Chen H, Mayo L, et al.: **RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS**. *Science* 2016, **353**:603-608.
29. Kondylis V, Polykratis A, Ehlken H, Ochoa-Callejero L, Straub BK, Krishna-Subramanian S, Van TM, Curth HM, Heise N, Weih F, et al.: **NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis**. *Cancer Cell* 2015, **28**:582-598.



30. Berger SB, Kasparcova V, Hoffman S, Swift B, Dare L, Schaeffer M, Capriotti C, Cook M, Finger J, Hughes-Earle A, et al.: **Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice.** *J Immunol* 2014, **192**:5476-5480.
31. Varfolomeev E, Vucic D: **Intracellular regulation of TNF activity in health and disease.** *Cytokine* 2018, **101**:26-32.
32. Peltzer N, Darding M, Walczak H: **Holding RIPK1 on the Ubiquitin Leash in TNFR1 Signaling.** *Trends Cell Biol* 2016, **26**:445-461.
33. Annibaldi A, Meier P: **Checkpoints in TNF-Induced Cell Death: Implications in Inflammation and Cancer.** *Trends Mol Med* 2018, **24**:49-65.
34. Feltham R, Silke J: **The small molecule that packs a punch: ubiquitin-mediated regulation of RIPK1/FADD/caspase-8 complexes.** *Cell Death Differ* 2017, **24**:1196-1204.
35. Justus SJ, Ting AT: **Cloaked in ubiquitin, a killer hides in plain sight: the molecular regulation of RIPK1.** *Immunol Rev* 2015, **266**:145-160.
36. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ: **Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO.** *Mol Cell* 2006, **22**:245-257.
37. Zhang X, Zhang H, Xu C, Li X, Li M, Wu X, Pu W, Zhou B, Wang H, Li D, et al.: **Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis.** *Nat Commun* 2019, **10**:4158.

- This study showed that mutation of lysine 376 inhibits ubiquitination of RIPK1 causing apoptosis and necroptosis and embryonic lethality in mice.

38. Tang Y, Tu H, Zhang J, Zhao X, Wang Y, Qin J, Lin X: **K63-linked ubiquitination regulates RIPK1 kinase activity to prevent cell death during embryogenesis and inflammation.** *Nat Commun* 2019, **10**:4157.

- This study showed that mutation of lysine 376 inhibits ubiquitination of RIPK1 causing apoptosis and necroptosis and embryonic lethality in mice.

39. Menon MB, Gropengiesser J, Fischer J, Novikova L, Deuretzbacher A, Lafera J, Schimmeck H, Czymmeck N, Ronkina N, Kotlyarov A, et al.: **p38(MAPK)/MK2-dependent phosphorylation controls cytotoxic RIPK1 signalling in inflammation and infection.** *Nat Cell Biol* 2017, **19**:1248-1259.

- This study showed that MK2-dependent phosphorylation of RIPK1 limits TNF-induced cell death.

40. Jaco I, Annibaldi A, Lalaoui N, Wilson R, Tenev T, Laurien L, Kim C, Jamal K, Wicky John S, Liccardi G, et al.: **MK2 Phosphorylates RIPK1 to Prevent TNF-Induced Cell Death.** *Mol Cell* 2017, **66**:698-710 e695.

- This study showed that MK2-dependent phosphorylation of RIPK1 limits TNF-induced cell death.

41. Dondelinger Y, Delanghe T, Rojas-Rivera D, Priem D, Delvaeye T, Bruggeman I, Van Herreweghe F, Vandenabeele P, Bertrand MJM: **MK2 phosphorylation of RIPK1 regulates TNF-mediated cell death.** *Nat Cell Biol* 2017, **19**:1237-1247.

- This study showed that MK2-dependent phosphorylation of RIPK1 limits TNF-induced cell death.

42. Geng J, Ito Y, Shi L, Amin P, Chu J, Ouchida AT, Mookhtiar AK, Zhao H, Xu D, Shan B, et al.: **Regulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis.** *Nat Commun* 2017, **8**:359.
- This study showed that TAK1 is required for RIPK1 phosphorylation that limits TNF-induced cell death.
43. Dondelinger Y, Jouan-Lanhouet S, Divert T, Theatre E, Bertin J, Gough PJ, Giansanti P, Heck AJ, Dejardin E, Vandenabeele P, et al.: **NF-kappaB-Independent Role of IKKalpha/IKKbeta in Preventing RIPK1 Kinase-Dependent Apoptotic and Necroptotic Cell Death during TNF Signaling.** *Mol Cell* 2015, **60**:63-76.
44. Dondelinger Y, Delanghe T, Priem D, Wynosky-Dolfi MA, Sorobetea D, Rojas-Rivera D, Giansanti P, Roelandt R, Gropengiesser J, Ruckdeschel K, et al.: **Serine 25 phosphorylation inhibits RIPK1 kinase-dependent cell death in models of infection and inflammation.** *Nat Commun* 2019, **10**:1729.
- This study provided genetic and biochemical proof that phosphorylation of serine 25 of RIPK1 by IKKs prevents RIPK1 kinase activation, cell death and inflammation.
45. Xu D, Jin T, Zhu H, Chen H, Ofengeim D, Zou C, Mifflin L, Pan L, Amin P, Li W, et al.: **TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging.** *Cell* 2018, **174**:1477-1491 e1419.
- This study showed that TBK1 phosphorylates RIPK1 to prevent cell death and that inhibition of RIPK1 kinase activity rescued embryonic lethality of TBK1 knockout mice.
46. Lafont E, Draber P, Rieser E, Reichert M, Kupka S, de Miguel D, Draberova H, von Massenhausen A, Bhamra A, Henderson S, et al.: **TBK1 and IKKepsilon prevent TNF-induced cell death by RIPK1 phosphorylation.** *Nat Cell Biol* 2018, **20**:1389-1399.
- This study showed that TBK1 and IKKepsilon phosphorylate RIPK1 to prevent TNF-induced cell death.
47. Degtarev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X, Abbott D, Cuny GD, Yuan C, Wagner G, et al.: **Identification of RIP1 kinase as a specific cellular target of necrostatins.** *Nat Chem Biol* 2008, **4**:313-321.
48. Zhang Y, Su SS, Zhao S, Yang Z, Zhong CQ, Chen X, Cai Q, Yang ZH, Huang D, Wu R, et al.: **RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome.** *Nat Commun* 2017, **8**:14329.
49. Lin Y, Devin A, Rodriguez Y, Liu ZG: **Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis.** *Genes Dev* 1999, **13**:2514-2526.
50. Feng S, Yang Y, Mei Y, Ma L, Zhu DE, Hoti N, Castanares M, Wu M: **Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain.** *Cell Signal* 2007, **19**:2056-2067.
51. O'Donnell MA, Perez-Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R, Green DR, Ting AT: **Caspase 8 inhibits programmed necrosis by processing CYLD.** *Nat Cell Biol* 2011, **13**:1437-1442.

52. Pop C, Oberst A, Drag M, Van Raam BJ, Riedl SJ, Green DR, Salvesen GS: **FLIP(L) induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity.** *Biochem J* 2011, **433**:447-457.
53. Zhang X, Dowling JP, Zhang J: **RIPK1 can mediate apoptosis in addition to necroptosis during embryonic development.** *Cell Death Dis* 2019, **10**:245.
- · This study showed that inhibition of RIPK1 cleavage by caspase-8 causes embryonic lethality that could be inhibited by combined inhibition of caspase-8-dependent apoptosis and RIPK3-MLKL-dependent necroptosis.
54. Tao P, Sun J, Wu Z, Wang S, Wang J, Li W, Pan H, Bai R, Zhang J, Wang Y, et al.: **A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1.** *Nature* 2019.
- · This study showed that patients heterozygous for mutations that prevent the cleavage of RIPK1 by caspase-8 develop periodic fever and lymphadenopathy and that cleavage of RIPK1 by caspase-8 prevents apoptosis and necroptosis.
55. Newton K, Wickliffe KE, Dugger DL, Maltzman A, Roose-Girma M, Dohse M, Komuves L, Webster JD, Dixit VM: **Cleavage of RIPK1 by caspase-8 is crucial for limiting apoptosis and necroptosis.** *Nature* 2019, **574**:428-431.
- · This study showed that cleavage of RIPK1 by caspase-8 prevents apoptosis and necroptosis and that knock-in mice expressing RIPK1 with mutation of the caspase-8 cleavage site die during embryogenesis due to caspase-8-dependent apoptosis and RIPK3-MLKL-dependent necroptosis.
56. Lalaoui N, Boyden SE, Oda H, Wood GM, Stone DL, Chau D, Liu L, Stoffels M, Kratina T, Lawlor KE, et al.: **Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease.** *Nature* 2019.
- · This study showed that patients heterozygous for mutations that prevent the cleavage of RIPK1 by caspase-8 develop periodic fever and lymphadenopathy. Also showed that cleavage of RIPK1 by caspase-8 prevents apoptosis and necroptosis and that knock-in mice expressing RIPK1 with mutation of the caspase-8 cleavage site die during embryogenesis due to caspase-8-dependent apoptosis and RIPK3-MLKL-dependent necroptosis.
57. Newton K, Wickliffe KE, Maltzman A, Dugger DL, Reja R, Zhang Y, Roose-Girma M, Modrusan Z, Sagolla MS, Webster JD, et al.: **Activity of caspase-8 determines plasticity between cell death pathways.** *Nature* 2019, **575**:679-682.
- · This study showed that mutation of the catalytic site of caspase-8 caused lethality in mice that depended on MLKL-mediated necroptosis and ASC-Caspase-1 inflammasome activation. Also provided evidence that MLKL-mediated necroptosis limits inflammasome activation and severe pathology in the intestine of mice expressing catalytically inactive caspase-8.
58. Fritsch M, Gunther SD, Schwarzer R, Albert MC, Schorn F, Werthenbach JP, Schiffmann LM, Stair N, Stocks H, Seeger JM, et al.: **Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis.** *Nature* 2019, **575**:683-687.

· This study showed that mutation of the catalytic site of caspase-8 caused lethality in mice that depended on MLKL-mediated necroptosis and ASC-Caspase-1 inflammasome activation. Also provided evidence that MLKL-mediated necroptosis limits inflammasome activation and severe pathology in the intestine of mice expressing catalytically inactive caspase-8.

59. Alvarez-Diaz S, Dillon CP, Lalaoui N, Tanzer MC, Rodriguez DA, Lin A, Lebois M, Hakem R, Josefsson EC, O'Reilly LA, et al.: **The Pseudokinase MLKL and the Kinase RIPK3 Have Distinct Roles in Autoimmune Disease Caused by Loss of Death-Receptor-Induced Apoptosis.** *Immunity* 2016, **45**:513-526.
60. Lehle AS, Farin HF, Marquardt B, Michels BE, Magg T, Li Y, Liu Y, Ghalandary M, Lammens K, Hollizeck S, et al.: **Intestinal Inflammation and Dysregulated Immunity in Patients With Inherited Caspase-8 Deficiency.** *Gastroenterology* 2019, **156**:275-278.

· This study reported that patients with genetic caspase-8 deficiency suffer from intestinal inflammation and systemic immune dysregulation.

61. Niemela J, Kuehn HS, Kelly C, Zhang M, Davies J, Melendez J, Dreiling J, Kleiner D, Calvo K, Oliveira JB, et al.: **Caspase-8 Deficiency Presenting as Late-Onset Multi-Organ Lymphocytic Infiltration with Granulomas in two Adult Siblings.** *J Clin Immunol* 2015, **35**:348-355.
62. Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, Dale JK, Puck J, Davis J, Hall CG, et al.: **Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency.** *Nature* 2002, **419**:395-399.
63. Wang Y, Gao W, Shi X, Ding J, Liu W, He H, Wang K, Shao F: **Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin.** *Nature* 2017, **547**:99-103.

· This study showed that caspase-3 cleaves GSDME to induce lytic cell death and that activation of GSDME contributes to chemotherapy-induced systemic pathology.

64. Rogers C, Fernandes-Alnemri T, Mayes L, Alnemri D, Cingolani G, Alnemri ES: **Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death.** *Nat Commun* 2017, **8**:14128.

· This study showed that caspase-3 cleaves GSDME to induce lytic cell death described as secondary necrosis.

65. Chen KW, Demarco B, Heilig R, Shkarina K, Boettcher A, Farady CJ, Pelczar P, Broz P: **Extrinsic and intrinsic apoptosis activate pannexin-1 to drive NLRP3 inflammasome assembly.** *EMBO J* 2019, **38**.
66. Sarhan J, Liu BC, Muendlein HI, Li P, Nilson R, Tang AY, Rongvaux A, Bunnell SC, Shao F, Green DR, et al.: **Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during Yersinia infection.** *Proc Natl Acad Sci U S A* 2018, **115**:E10888-E10897.

· This study showed that inhibition of TAK1 by chemical inhibitors or the Yersinia effector YopJ causes caspase-8-dependent cleavage of GSDMD and pyroptosis.

67. Orning P, Weng D, Starheim K, Ratner D, Best Z, Lee B, Brooks A, Xia S, Wu H, Kelliher MA, et al.: **Pathogen blockade of TAK1 triggers caspase-8-**

**dependent cleavage of gasdermin D and cell death.** *Science* 2018, **362**:1064-1069.

· This study showed that inhibition of TAK1 by chemical inhibitors or the Yersinia effector YopJ causes caspase-8-dependent cleavage of GSDMD and pyroptosis.

68. Taabazuing CY, Okondo MC, Bachovchin DA: **Pyroptosis and Apoptosis Pathways Engage in Bidirectional Crosstalk in Monocytes and Macrophages.** *Cell Chem Biol* 2017, **24**:507-514 e504.

69. Kang TB, Yang SH, Toth B, Kovalenko A, Wallach D: **Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome.** *Immunity* 2013, **38**:27-40.

70. Kang S, Fernandes-Alnemri T, Rogers C, Mayes L, Wang Y, Dillon C, Roback L, Kaiser W, Oberst A, Sagara J, et al.: **Caspase-8 scaffolding function and MLKL regulate NLRP3 inflammasome activation downstream of TLR3.** *Nat Commun* 2015, **6**:7515.

71. Conos SA, Chen KW, De Nardo D, Hara H, Whitehead L, Nunez G, Masters SL, Murphy JM, Schroder K, Vaux DL, et al.: **Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner.** *Proc Natl Acad Sci U S A* 2017, **114**:E961-E969.

· This study showed that MLKL activation triggers NLRP3 inflammasome activation in a cell intrinsic manner by damaging the plasma membrane inducing potassium efflux.

72. Polykratis A, Martens A, Eren RO, Shirasaki Y, Yamagishi M, Yamaguchi Y, Uemura S, Miura M, Holzmann B, Kollias G, et al.: **A20 prevents inflammasome-dependent arthritis by inhibiting macrophage necroptosis through its ZnF7 ubiquitin-binding domain.** *Nat Cell Biol* 2019, **21**:731-742.

· This study showed that RIPK1-RIPK3-MLKL-dependent necroptosis of A20-deficient myeloid cells triggers NLRP3 inflammasome activation and IL-1-dependent arthritis in mice.

73. Lawlor KE, Khan N, Mildenhall A, Gerlic M, Croker BA, D'Cruz AA, Hall C, Kaur Spall S, Anderton H, Masters SL, et al.: **RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL.** *Nat Commun* 2015, **6**:6282.

74. Chauhan D, Bartok E, Gaidt MM, Bock FJ, Herrmann J, Seeger JM, Broz P, Beckmann R, Kashkar H, Tait SWG, et al.: **BAX/BAK-Induced Apoptosis Results in Caspase-8-Dependent IL-1beta Maturation in Macrophages.** *Cell Rep* 2018, **25**:2354-2368 e2355.

75. Chen KW, Lawlor KE, von Pein JB, Boucher D, Gerlic M, Croker BA, Bezbradica JS, Vince JE, Schroder K: **Cutting Edge: Blockade of Inhibitor of Apoptosis Proteins Sensitizes Neutrophils to TNF- but Not Lipopolysaccharide-Mediated Cell Death and IL-1beta Secretion.** *J Immunol* 2018, **200**:3341-3346.

76. Malireddi RKS, Gurung P, Mavuluri J, Dasari TK, Klco JM, Chi H, Kanneganti TD: **TAK1 restricts spontaneous NLRP3 activation and cell death to control myeloid proliferation.** *J Exp Med* 2018, **215**:1023-1034.

77. Vince JE, Wong WW, Gentle I, Lawlor KE, Allam R, O'Reilly L, Mason K, Gross O, Ma S, Guarda G, et al.: **Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation.** *Immunity* 2012, **36**:215-227.


78. Wicki S, Gurzeler U, Wei-Lynn Wong W, Jost PJ, Bachmann D, Kaufmann T: **Loss of XIAP facilitates switch to TNFalpha-induced necroptosis in mouse neutrophils.** *Cell Death Dis* 2016, **7**:e2422.

### **Acknowledgments**

Research in the authors' laboratory is supported by grants from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, projects SFB829, SFB1218, SFB1399, SFB1403, TR259, GRK 2407, PA 1476/8-1), the BMBF (e:med project InCa) and the European Research Council (AdG 787826).

### **Declaration of competing interests**

M.P. received consulting and speaker fees from Genentech, GSK, Boehringer Ingelheim and Sanofi.



**Figure 1. Caspase-8 regulates apoptosis, necroptosis and pyroptosis.**

Schematic depiction of the functions of caspase-8 in regulating apoptosis, necroptosis and pyroptosis. Left panel: caspase-8 acts as the initiator caspase in the extrinsic apoptosis pathway inducing activation of the effector caspases 3, 6 and 7 causing apoptotic cell death. GSDME cleavage by caspase-3 as well as GSDMD cleavage by caspase-8 can trigger lytic cell death resembling pyroptosis. Caspase-8 also inhibits necroptosis by cleaving RIPK1 and perhaps other proteins regulating necroptosis such as RIPK3. Right panel: loss of caspase-8 activity allows activation of necroptosis. Expression of catalytically inactive caspase-8 causes the activation of the ASC/caspase-1 inflammasome resulting in GSDMD-mediated pyroptosis. KD, kinase domain; DD, death domain; DED, death effector domain; R, RHIM; CARD, caspase recruitment domain; PYR, pyrin domain.